Cargando…
Gemcitabine-Induced Myositis in a Luminal B Breast Cancer patient: A Case Report
Human epidermal growth factor receptor-positive breast cancer is an aggressive cancer which represents approximately a quarter of all breast cancers worldwide. Recent advances have led to the development of targeted therapies, such as trastuzumab (H), which have significantly improved prognosis. Suc...
Autores principales: | Badran, Ahmed, Ali, Saad Salman, Arabi, Tarek Ziad, Hinkston, Abdullaah Khaleel, Shaik, Abdullah, Elshenawy, Mahmoud A, Ajarim, Dahish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941597/ https://www.ncbi.nlm.nih.gov/pubmed/36824292 http://dx.doi.org/10.1177/11795476231156290 |
Ejemplares similares
-
Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021) -
Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
por: Al-Tweigeri, Taher, et al.
Publicado: (2021) -
Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial
por: Bazarbashi, Shouki, et al.
Publicado: (2022) -
Obesity is a significant risk factor for breast cancer in Arab women
por: Elkum, Naser, et al.
Publicado: (2014) -
Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis
por: Chun, June Young, et al.
Publicado: (2017)